Compare JAZZ & EHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JAZZ | EHC |
|---|---|---|
| Founded | 2003 | 1983 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Hospital/Nursing Management |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.4B | 10.6B |
| IPO Year | 2007 | 1994 |
| Metric | JAZZ | EHC |
|---|---|---|
| Price | $239.49 | $104.94 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 7 |
| Target Price | ★ $217.57 | $143.29 |
| AVG Volume (30 Days) | 843.6K | ★ 891.7K |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 0.74% |
| EPS Growth | N/A | ★ 24.22 |
| EPS | ★ 4.43 | 1.93 |
| Revenue | ★ $1,618,693,000.00 | N/A |
| Revenue This Year | $6.22 | $9.33 |
| Revenue Next Year | $7.68 | $8.14 |
| P/E Ratio | ★ $54.00 | $54.03 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $105.00 | $92.77 |
| 52 Week High | $242.18 | $127.99 |
| Indicator | JAZZ | EHC |
|---|---|---|
| Relative Strength Index (RSI) | 76.38 | 50.06 |
| Support Level | $128.87 | $98.26 |
| Resistance Level | N/A | $109.37 |
| Average True Range (ATR) | 6.06 | 3.07 |
| MACD | 0.92 | -0.22 |
| Stochastic Oscillator | 89.49 | 44.68 |
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Encompass Health Corp provides post-acute healthcare services in the United States through a network of inpatient rehabilitation hospitals, which is the company's sole segment. Inpatient rehabilitation contributes the majority of the firm's revenue and provides specialized rehabilitative treatment through a network of inpatient hospitals. The company's inpatient rehabilitation hospitals provide a higher level of rehabilitative care to patients who are recovering from conditions such as stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions, and amputations.